Q-omics provides the consensus-scored GPR52 profile across patient tissues and cancer cell-line models. GPR52 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, GPR52 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, GPR52 RNA expression shows 13,419 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight SCLC, BRCA, and DLBC as cancer lineages where GPR52 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR52 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR52 survival associations across molecular data types. GPR52 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR52 RNA expression–survival associations across cancer types. High GPR52 expression shows unfavorable associations in ACC, KIRC, LIHC, PCPG and PRAD, but favorable associations in SCLC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for GPR52 RNA expression.
This table summarizes GPR52 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GPR52. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR52 shows lower tumor expression in STAD and THCA and higher tumor expression in BRCA, HNSC, BLCA and CHOL. The BRCA box plot shows higher GPR52 RNA expression in tumor versus normal tissue (log2 FC = +0.166, t-test p = .021).
This table shows molecular features associated with GPR52 in patient tissues and cancer cell lines. In patient samples, GPR52 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR52 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
